Epstein Secrets

From: Boris Nikolic To: Jeffrey Epstein <[email protected]> Subject: RE: FW: Yesterday Date: Mon, 20 May 2013 00:30:13 +0000 I will be OK — do not worry. Fragile might not be a righ

From: Boris Nikolic To: Jeffrey Epstein <[email protected]> Subject: RE: FW: Yesterd

From: Boris Nikolic To: Jeffrey Epstein <[email protected]> Subject: RE: FW:

ion. I am afraid that a) these neovascularizations have progressed somewhat fast (these were not there at all in February). If we count that my last Lucentis was given on January 28th and perhaps has worked for 3 months or so would indicate that these two neovascularizations are only month old or so. b)

in my vision on my right eye, I was somewhat shaken. THANK YOU AGAIN for you care. EFTA00631539 My only question to you is whether I still need a Lucentis injection. I am afraid that a) these neovascularizations have progressed somewhat fast (these were not there at all in February). If we count that m

To: Boris Nikolic From: Jeffrey Epstein Sent Mon 5/20/2013 12:26:46 AM Subject Re: FW: Yesterday I thanks , i sincerely appreciate the trust, I have no idea of the facts. But I am aware

To: Boris Nikolic From: Jeffrey Epstein Sent Mon 5/20/2013 12:26:46 AM Subject Re: FW:

To: Boris Nikolic From: Jeffrey Epstein Sent Mon 5/20/2013 12:26:46 AM Subject

on. I am afraid that a) these neovascularizations have progressed somewhat fast (these were not there at all in February). If we count that my last Lucentis was given on January 28th and perhaps has worked for 3 months or so would indicate that these two neovascularizations are only month old or so. b)

) improvement in my vision on my right eye, I was somewhat shaken. THANK YOU AGAIN for you care. My only question to you is whether I still need a Lucentis injection. I am afraid that a) these neovascularizations have progressed somewhat fast (these were not there at all in February). If we count that

From: Vahe Stepanian To: Jeffrey Epstein <[email protected]> Morris Stewart Oldfield , Richard Kahn , Ariane Dwyer , Paul CC: Daniel Sabba Subject: AAVL: (BN) Avalanche Drops as G

ps as Gene Therapy Trial Miss High Expectation [C] Date: Tue, 16 Jun 2015 14:02:02 +0000 Inline-Images: image002.jpg Classification: Confidential Jeffrey — we are following up with the below news regarding AAVL. The stock is trading down $19.11 to $19.7657 per the Bloomberg screenshot below. Please l

From: Vahe Stepanian To: Jeffrey Epstein <[email protected]> Morris Stewart Oldfield

designed to show statistically significant differences, the group treated with AVA-101 got an average of two extra injections of Roche Holding AG's Lucentis, compared with four for the control group. "When a company is valued at $1 billion at a phase 2 trial, the expectations are quite high," said Gbola

To: Jeffrey epstein ([email protected])[jeffrey epstein (jeevacation@gmailcom)); [email protected][[email protected]) From: Boris Nikolic Sent: Sun 5/19

To: Jeffrey epstein ([email protected])[jeffrey epstein (

on. I am afraid that a) these neovascularizations have progressed somewhat fast (these were not there at all in February). If we count that my last Lucentis was given on January 28th and perhaps has worked for 3 months or so would indicate that these two neovascularizations are only month old or so. b)

) improvement in my vision on my right eye, I was somewhat shaken. THANK YOU AGAIN for you care. My only question to you is whether I still need a Lucentis injection. I am afraid that a) these neovascularizations have progressed somewhat fast (these were not there at all in February). If we count that